rAAVrh74.MHCK7.DYSF.DV for Treatment of Dysferlinopathies

Dysferlinopathy Clinical Trial

Official title:

Phase I Intramuscular Gene Transfer Clinical Trial for Dysferlin Deficiency Delivering the Dysferlin Gene by AAVrh74

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02710500
• Other study ID #: IRB15-00669
• Status: Completed
• Phase: Phase 1
• Start date: March 2016
• Est. completion date: July 2019

Study information

• Verified date: May 2021
• Source: Sarepta Therapeutics, Inc.
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The proposed clinical trial is a double-blind, randomized controlled study with direct intramuscular injection of rAAVrh.74.MHCK7.DYSF.DV gene vector to the extensor digitorum brevis muscle (EDB). Two cohorts of subjects with dysferlin deficiency, each with proven mutations will undergo gene transfer. A minimum of three subjects will be enrolled into each cohort.

Description:

This is a phase I safety and tolerability study with a direct intramuscular injection of rAAVrh.74.MHCK7.DYSF.DV transferred to the extensor digitorum brevis muscle (EDB). The study is designed as a randomized, controlled, dose escalation trial with one EDB receiving the rAAVrh.74.MHCK7.DYSF.DV and the other side receiving saline alone. It will follow the previously safe and effective IM gene transfer to EDB for LGMD2D.2, 3 The first cohort, inclusive of three Dysferlinopathy subjects, will receive a gene transfer total dose of 2 x 10^12 vector genomes. Muscle biopsies will be performed at Day 45 (two subjects) and Day 90 (one subject). If there are no safety concerns, three additional subjects will be enrolled and receive an escalated dose at 6 X 10^12 vg (total dose). Muscle biopsies in the second cohort will be performed at Day 90 (one subject) and Day 180 (two subjects). This protocol design gives us a maximum period of observation ranging from 6 weeks to 6 months to capture both transient and delayed gene expression, and to recognize sustained expression.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 2
• Est. completion date: July 2019
• Est. primary completion date: July 2019
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Must be Non-ambulant (cannot walk 10 meters in = 30 sec) and age 18 years or older

• Established mutations of the dysferlin gene on both alleles

• Impaired muscle function but with sufficient muscle preservation to ensure muscle transfection based on magnetic resonance image of the EDB showing sufficient muscle preservation to permit transfection

• Willingness of sexually active subjects with reproductive capacity to practice reliable method of contraception (If appropriate), during the first six months after gene transfer (females) or until two negative sperm samples are obtained post gene transfer (males).

Exclusion Criteria:

• Active viral infection based on clinical observations or serological evidence of HIV, or Hepatitis A, B or C infection

• The presence of a Dysferlin mutations without weakness or loss of function

• Symptoms or signs of cardiomyopathy, including:

• Dyspnea on exertion, pedal edema, shortness of breath upon lying flat, or rales at the base of the lungs

• Echocardiogram with ejection fraction below 40%

• Diagnosis of (or ongoing treatment for) an autoimmune disease

• Persistent leukopenia or leukocytosis (WBC = 3.5 K/µL or = 20.0 K/µL) or an absolute neutrophil count < 1.5K/µL

• Concomitant illness or requirement for chronic drug treatment that in the opinion of the PI creates unnecessary risks for gene transfer

• Pregnancy

• AAVrh74 or AAV8 binding antibody titers > 1:50 as determined by ELISA immunoassay

• Abnormal laboratory values in the clinically significant range in the table below, based upon normal values in the Nationwide Children's Hospital Laboratory: GGT, Total Bilirubin, Cystatine, Hemoglobin, White Blood Cells

Related Conditions & MeSH terms

• Dysferlinopathy

Intervention

Drug:
• rAAVrh74.MHCK7.DYSF.DV
Biological/Vaccine: rAAVrh74.MHCK7.DYSF.DV Recombinant adeno-associated virus carrying a dysferlin transgene under control of a muscle specific MHCK7 promoter.

Locations

Country	Name	City	State
United States	Nationwide Children's Hosptial	Columbus	Ohio

Sponsors (1)

Lead Sponsor	Collaborator
Sarepta Therapeutics, Inc.

Country where clinical trial is conducted

United States, 

References & Publications (2)

Grose WE, Clark KR, Griffin D, Malik V, Shontz KM, Montgomery CL, Lewis S, Brown RH Jr, Janssen PM, Mendell JR, Rodino-Klapac LR. Homologous recombination mediates functional recovery of dysferlin deficiency following AAV5 gene transfer. PLoS One. 2012;7(6):e39233. doi: 10.1371/journal.pone.0039233. Epub 2012 Jun 15. — View Citation

Sondergaard PC, Griffin DA, Pozsgai ER, Johnson RW, Grose WE, Heller KN, Shontz KM, Montgomery CL, Liu J, Clark KR, Sahenk Z, Mendell JR, Rodino-Klapac LR. AAV.Dysferlin Overlap Vectors Restore Function in Dysferlinopathy Animal Models. Ann Clin Transl Neurol. 2015 Mar;2(3):256-70. doi: 10.1002/acn3.172. Epub 2015 Jan 20. — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Determination of safety based on the development of unacceptable toxicity	Defined as the occurrence of any one Grade III or higher, unanticipated, treatment-related toxicity	2 Years
Secondary	Number of participants showing dysferlin protein expression in muscle tissue	More than 3 fold increase in dysferlin protein expression in muscle compared to control side by western blot or more than 30% increase in dysferlin-expressing fibers; Dysferlin protein expression as demonstrated with N -terminal anti-dysferlin antibodies will be quantified using BioQuant	2 Years
Secondary	Leukocyte marker counts including CD45, CD3, CD4, CD8, and MAC 387.	Number of CD4+ cells/ mm2 area; Number of CD8+ cells/ mm2 area; Number of muscle fibers expressing MHCI staining / mm2 area; Number of muscle fibers expressing MHCII staining / mm2 area	2 Years
Secondary	Binding antibodies counts and ELISpot counts to both rAAVrh74 capsid and dysferlin protein.	AAVrh74 or AAV8 binding antibody titers > 1:50 as determined by ELISA immunoassay	2 Years
Secondary	Number of inflammatory cells in muscle	Number of inflammatory cells per mm2 area	2 Years

External Links

•   Center for Gene Therapy, The Research Institute at Nationwide Children's Hospital